Securing meaningful media coverage is one of the most effective ways to build visibility, credibility and reputation among investors, partners, customers and the wider life sciences community.

We help companies develop compelling stories that resonate with both specialist life sciences media and influential business and financial journalists. Drawing on our extensive industry knowledge and established media relationships, we identify the stories that matter, position them effectively and secure opportunities that raise awareness and support business objectives.

From financing announcements and clinical milestones to partnering deals and corporate developments, we provide strategic counsel on how and when to engage with the media. We also ensure executives are fully prepared to communicate with confidence through tailored media training, messaging and Q&A preparation.

Services

  • Media strategy & counsel
  • Message development
  • Media relations
  • Press releases
  • Media interviews
  • Media training
  • Q&A development
  • Media factsheets
  • Thought leadership articles
  • Commentary and feature opportunities
  • Digital & social media campaigns

Case Studies

Advent Life Sciences

Showcasing the significance of two new funds

Amphista Therapeutics

Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

Anocca

Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology

BC Platforms

Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.

Epitopea USD $31 Million Pre-Series A Financing

Supporting Epitopea’s $31M Pre-Series A financing with high-impact media coverage, raising visibility for CryptoMap™ and strengthening investor and partner engagement.

ExeVir Bio EIB funding case study

Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic

Igyxos: Raising the profile of a novel infertility treatment

Positioning Igyxos as a thought leader in monoclonal-based fertility innovation and elevating its profile ahead of clinical and investor milestones.

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

LEX Diagnostics | FDA 510(k) Clearance and CLIA Waiver Approval for LEX VELO System

Supporting LEX Diagnostics’ FDA submissions and takeover bid, contributing to its $100m acquisition.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

Microbiotica : First patient dosed announcements

Announcing the first patient dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking significant progress for Microbiotica in its transition to a clinical-stage company.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

MONCYTE Health Secures €1M Seed Funding to Advance Personalized Cardiovascular Treatment

Strategic support to amplify MONCYTE Health’s €1M seed round and boost visibility among investors and industry stakeholders.

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

Raising the profile of Scarlet Therapeutics

Supporting Scarlet Therapeutics in communicating a major platform validation milestone and £3.2 million seed financing, raising visibility with investors, partners and industry stakeholders.

TILT Biotherapeutics

Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.

TILT Biotherapeutics €22 Million Financing

Supporting TILT Biotherapeutics and their final close of €22 Million financing

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing 

VaxEquity Strategic Collaboration with AstraZeneca

Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform

Advent Life Sciences

Showcasing the significance of two new funds

Amphista Therapeutics

Announcing the company’s Series A financing, leading to raised awareness with potential partners, investors and employees.

Amphista Therapeutics: Series B Financing

Announcing the company's Series B financing, which will be used to accelerate the growing pipeline of potent and selective bifunctional molecules and to extend its proprietary TPD platform.

Anocca

Announcing the company's strategic collaboration with Shinobi Therapeutics to to develop allogeneic TCR-T cell therapies in oncology

BC Platforms

Positioning the company as a thought leader in precision medicine raising awareness with customers and investors.

Epitopea Strategic Cancer Collaboration with MSD(Merck)

Announcing the company's strategic cancer collaboration with major global pharma company, positioning client as a pioneer in developing off-the-shelf immunotherapies.

Epitopea USD $31 Million Pre-Series A Financing

Supporting Epitopea’s $31M Pre-Series A financing with high-impact media coverage, raising visibility for CryptoMap™ and strengthening investor and partner engagement.

ExeVir Bio EIB funding case study

Announcing the company's 25 million Euro financing from EIB to advance ExeVir’s COVID19 therapeutic

Igyxos: Raising the profile of a novel infertility treatment

Positioning Igyxos as a thought leader in monoclonal-based fertility innovation and elevating its profile ahead of clinical and investor milestones.

IRBM

Positioning the Company as a leading CDMO and highlighting their group Advaxia Biologics.

LEX Diagnostics | FDA 510(k) Clearance and CLIA Waiver Approval for LEX VELO System

Supporting LEX Diagnostics’ FDA submissions and takeover bid, contributing to its $100m acquisition.

Medicxi

To launch Index’s new spin-out life sciences fund and publicise its first closing.

Microbiotica : First patient dosed announcements

Announcing the first patient dosed (FPD) in two Phase 1b trials for MB310 (ulcerative colitis) and MB097 (advanced melanoma), marking significant progress for Microbiotica in its transition to a clinical-stage company.

MitoRx Case Study: Promoting a published paper

Promoting R&D findings on small molecule mitochondrial modulators

MONCYTE Health Secures €1M Seed Funding to Advance Personalized Cardiovascular Treatment

Strategic support to amplify MONCYTE Health’s €1M seed round and boost visibility among investors and industry stakeholders.

Pneumagen

Raising visibility of its technology platform for the treatment for COVID-19 and supporting a new website and fundraising announcement.

Raising the profile of Scarlet Therapeutics

Supporting Scarlet Therapeutics in communicating a major platform validation milestone and £3.2 million seed financing, raising visibility with investors, partners and industry stakeholders.

TILT Biotherapeutics

Showcasing Phase 1 clinical trial data for TILT-123 combination therapy for platinum-resistant or refractory ovarian cancer, presented at AACR and ASCO.

TILT Biotherapeutics €22 Million Financing

Supporting TILT Biotherapeutics and their final close of €22 Million financing

Vaccitech

Support with corporate and investor materials and media relations supporting the partnership of its ChAdOx platform with AstraZeneca for a COVID-19 vaccine.

Vaccitech IPO

Coordinated a communications plan with key stakeholders to maximise visibility of Vaccitech's Series B financing and NASDAQ IPO listing 

VaxEquity Strategic Collaboration with AstraZeneca

Announcing the company's strategic collaboration with AstraZeneca to Commercialise Self-Amplifying RNA platform